お知らせ • Apr 27
Burcon NutraScience Corporation announced that it has received CAD 6.9 million in funding from RE ProMan LLC On April 27, 2026, Burcon NutraScience Corporation closed the transaction. The company announced that it has issued convertible debentures for gross proceeds of CAD 2,900,000 in final tranche. An insider of the Company subscribed for Convertible Debentures totaling approximately CAD 1,700,000 in principal amount under the final tranche. In total, insiders of the Company subscribed for Convertible Debentures totaling approximately CAD 4,400,000 in principal amount in aggregate under the Private Placement. New Risk • Feb 13
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$8.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$8.1m free cash flow). Negative equity (-CA$2.5m). Minor Risks Revenue is less than US$5m (CA$1.5m revenue, or US$1.1m). Market cap is less than US$100m (CA$24.2m market cap, or US$17.8m). Reported Earnings • Feb 13
Third quarter 2026 earnings released: CA$0.28 loss per share (vs CA$0.25 loss in 3Q 2025) Third quarter 2026 results: CA$0.28 loss per share (further deteriorated from CA$0.25 loss in 3Q 2025). Net loss: CA$3.58m (loss widened 100% from 3Q 2025). Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 2.8% growth forecast for the Chemicals industry in Canada. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Breakeven Date Change • Feb 12
Forecast breakeven date pushed back to 2028 The analyst covering Burcon NutraScience previously expected the company to break even in 2027. New forecast suggests losses will reduce by 51% per year to 2027. The company is expected to make a profit of CA$4.70m in 2028. Average annual earnings growth of 134% is required to achieve expected profit on schedule. お知らせ • Jan 28
Burcon NutraScience Corporation to Report Q3, 2026 Results on Feb 11, 2026 Burcon NutraScience Corporation announced that they will report Q3, 2026 results on Feb 11, 2026 Reported Earnings • Nov 14
Second quarter 2026 earnings: EPS and revenues miss analyst expectations Second quarter 2026 results: CA$0.28 loss per share. Net loss: CA$3.59m (loss widened 53% from 2Q 2025). Revenue missed analyst estimates by 29%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Canada. New Risk • Nov 14
New major risk - Revenue and earnings growth Earnings have declined by 17% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (78% increase in shares outstanding). Revenue is less than US$1m (CA$487k revenue, or US$347k). Minor Risk Market cap is less than US$100m (CA$29.1m market cap, or US$20.7m). お知らせ • Nov 13
Burcon NutraScience Corporation announced that it expects to receive CAD 4 million in funding Burcon NutraScience Corporation announced a non-brokered private placement to issue 4,000 convertible debentures at an issue price of CAD 1,000 per debenture for an aggregate principal amount of up to CAD 4,000,000 on November 12, 2025. Insiders of the Company have committed to participating at a minimum of CAD 2,000,000 in principal amount. The Offering is subject to the approval of the Toronto Stock Exchange ("TSX"). Each Convertible Debenture will consist of CAD 1,000 principal amount, bear interest at a rate of 15% per annum, payable in full upon maturity, and be unsecured. The principal amount outstanding under the Convertible Debentures and all accrued and unpaid interest thereon will be payable in cash 48 months from the date of issuance of the Convertible Debentures. The Convertible Debentures will be convertible at the option of the holder, in whole or in part, into common shares of the Corporation (the "Shares") at a conversion price of CAD 2.27 per Share (the "Conversion Price"). The Convertible Debentures and the Shares issuable upon conversion of the Convertible Debentures will be subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws. The Offering is expected to close on or about November 28, 2025 and is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX. お知らせ • Nov 06
Burcon NutraScience Corporation to Report Q2, 2026 Results on Nov 12, 2025 Burcon NutraScience Corporation announced that they will report Q2, 2026 results on Nov 12, 2025 New Risk • Aug 14
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -CA$6.6m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (79% increase in shares outstanding). Revenue is less than US$1m (CA$487k revenue, or US$353k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-CA$6.6m). Currently unprofitable and not forecast to become profitable next year (CA$804k net loss next year). Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (CA$34.6m market cap, or US$25.1m). Reported Earnings • Aug 14
First quarter 2026 earnings released: CA$0.27 loss per share (vs CA$0.26 loss in 1Q 2025) First quarter 2026 results: CA$0.27 loss per share (further deteriorated from CA$0.26 loss in 1Q 2025). Net loss: CA$3.48m (loss widened 86% from 1Q 2025). Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Canada. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. お知らせ • Jul 30
Burcon NutraScience Corporation to Report Q1, 2026 Results on Aug 13, 2025 Burcon NutraScience Corporation announced that they will report Q1, 2026 results on Aug 13, 2025 お知らせ • Jul 09
Burcon NutraScience Corporation, Annual General Meeting, Sep 17, 2025 Burcon NutraScience Corporation, Annual General Meeting, Sep 17, 2025. Location: british columbia, vancouver Canada お知らせ • Jul 02
Burcon NutraScience Corporation Unveils Cafe Latte Plant-Based Protein Beverage Concept Burcon NutraScience Corporation announced to unveil a Cafe Latte plant-based protein beverage concept at the upcoming Institute of Food Technologists Annual Meeting and Exposition ("IFT FIRST") in Chicago, IL, from July 13-16 in exhibit booth S4066. Cold Cafe Latte beverage containing plant proteins photo. The 2025 IFT FIRST food, beverage, foodservice, nutrition and nutraceuticals tradeshow will be held in Chicago July 13-16 and next-generation plant proteins will be front and center. Plant protein innovator Burcon NutraScience (Booth S4066) will feature its range of 90%+ pure pea, sunflower, canola, hemp and fava plant-based proteins with all featuring neutral flavor and aroma, and smooth mouthfeel. During the show, Burcon will be sampling a tasty cold Cafe Latte beverage containing 10 grams of high-purity pea and sunflower seed plant protein in a standard serving. IFT FIRST attendees will have the opportunity to sample the rich, coffee-inspired beverage made with Burcon's proprietary blend of Peazazz®?C pea protein and Solatein™? sunflower protein. The Cafe Latte contains 10 grams of plant protein in an eight-ounce serving showcasing the clean taste, smooth texture, and superior functionality of Burcon's high-purity protein ingredients-delivering an exceptional sensory. experience. In addition to the Cafe Latte, Burcon will exhibit its full portfolio of innovative plant-based proteins, each offering 90%+ protein purity, neutral flavor, and excellent performance for food, beverage, food service, nutritional, and nutraceutical applications. Featured Burcon protein ingredients on display at IFT FIRST include: Peazazz®? C - 90%+ pea protein. Puratein®? C - 90% + canola protein. Solatein™? - 90%+ sunflower protein and a sunflower protein concentrate. HPI95 - 90%+ hempseed protein. FavaPro™? - 90%+ fava protein. お知らせ • Jun 27
Burcon NutraScience Corporation Auditor Raises 'Going Concern' Doubt Burcon NutraScience Corporation filed its Annual on Jun 25, 2025 for the period ending Mar 31, 2025. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Breakeven Date Change • Jun 26
Forecast breakeven date pushed back to 2027 The analyst covering Burcon NutraScience previously expected the company to break even in 2026. New forecast suggests losses will reduce by 72% to 2026. The company is expected to make a profit of CA$3.70m in 2027. Average annual earnings growth of 126% is required to achieve expected profit on schedule. New Risk • Jun 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$82k). Shareholders have been substantially diluted in the past year (79% increase in shares outstanding). Revenue is less than US$1m (CA$339k revenue, or US$246k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (CA$48.0m market cap, or US$34.9m). お知らせ • Jun 17
Burcon NutraScience Corporation to Report Fiscal Year 2025 Results on Jun 25, 2025 Burcon NutraScience Corporation announced that they will report fiscal year 2025 results on Jun 25, 2025 お知らせ • Mar 11
Burcon NutraScience Corporation (TSX:BU) completed the acquisition of Protein Production Facility. Burcon NutraScience Corporation (TSX:BU) entered into a binding agreement to acquire Protein Production Facility on January 31, 2025. The closing of the transaction is subject to certain conditions, including satisfactory due diligence and approval by the parties.
Burcon NutraScience Corporation (TSX:BU) completed the acquisition of Protein Production Facility on March 10, 2025. Recent Insider Transactions Derivative • Feb 19
Chairman of the Board exercised options to buy CA$131k worth of stock. On the 13th of February, Peter Kappel exercised options to buy 1m shares at a strike price of around CA$0.085, costing a total of CA$123k. This transaction amounted to 100% of their direct individual holding at the time of the trade. Since March 2024, Peter has owned 1.45m shares directly. Company insiders have collectively bought CA$317k more than they sold, via options and on-market transactions, in the last 12 months. New Risk • Feb 18
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 108% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Negative equity (-CA$82k). Shareholders have been substantially diluted in the past year (108% increase in shares outstanding). Revenue is less than US$1m (CA$339k revenue, or US$238k). Minor Risk Market cap is less than US$100m (CA$25.4m market cap, or US$17.9m). New Risk • Feb 16
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$82k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Negative equity (-CA$82k). Revenue is less than US$1m (CA$339k revenue, or US$239k). Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CA$14.3m market cap, or US$10.1m). お知らせ • Feb 13
Burcon NutraScience Corporation has completed a Follow-on Equity Offering in the amount of CAD 9.433821 million. Burcon NutraScience Corporation has completed a Follow-on Equity Offering in the amount of CAD 9.433821 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 110,986,126
Price\Range: CAD 0.085
Transaction Features: Rights Offering お知らせ • Jan 09
Burcon Nutrascience Corporation Announces Launch of Solatein Sunflower Protein Is Now Available for Sampling Burcon NutraScience Corporation announced the launch of SolateinTM sunflower protein isolate, a groundbreaking high-purity protein ingredient designed to meet the evolving preferences of consumers worldwide. An emerging sector of consumers prioritizing protein intake is creating new opportunities for protein supplement products. According to Goldman Sachs Research, the number of GLP-1 weight management medication users is expected to increase rapidly over the next five years. These users are actively seeking protein to support their nutrition needs2. Burcon anticipates that its expanded portfolio of highly differentiated plant-based protein solutions is well-positioned to meet this significant demand. Burcon's SolateinTM sunflower protein is expected to redefine the standards for high-purity protein ingredients. It boasts a neutral flavor, off-white color and exceptional functionality, providing ease of formulation in a variety of food applications, in particular, those with delicate flavors. With over 90% protein purity, SolateinTM is a non-GMO, hypoallergenic protein that surpasses the performance of protein ingredients on the market today. It is rich in sulfur-containing amino acids, which enhances nutritional profiles and complements existing formulations. Burcon's innovative process upcycles by- products from sunflower seed oil production into a highly pure food ingredient, offering a sustainable protein solution. New Risk • Dec 06
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$11.4m (US$8.13m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (CA$277k revenue, or US$198k). Market cap is less than US$10m (CA$11.4m market cap, or US$8.13m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$1.5m net loss next year). Shareholders have been diluted in the past year (17% increase in shares outstanding). New Risk • Nov 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m (CA$277k revenue, or US$197k). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$1.5m net loss next year). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CA$28.5m market cap, or US$20.3m). お知らせ • Nov 22
Burcon NutraScience Corporation has filed a Follow-on Equity Offering in the amount of CAD 8.671788 million. Burcon NutraScience Corporation has filed a Follow-on Equity Offering in the amount of CAD 8.671788 million.
Security Name: Common Share
Security Type: Common Stock
Securities Offered: 142,628,096
Price\Range: CAD 0.0608
Transaction Features: Rights Offering お知らせ • Oct 30
Burcon NutraScience Corporation to Report Q2, 2025 Results on Nov 13, 2024 Burcon NutraScience Corporation announced that they will report Q2, 2025 results on Nov 13, 2024 お知らせ • Oct 09
Burcon NutraScience Corporation Launches Puratein® Canola Protein Burcon NutraScience Corporation announced the launch of its Puratein® canola protein into the rapidly growing, multi-billion-dollar egg replacement market. Burcon's canola protein is well-suited for use in baked goods, offering food manufacturers a sustainable and cost- effective alternative to eggs. Egg prices have surged due to supply challenges, with demand outpacing production in the U.S. Over the past two years, avian influenza outbreaks have significantly disrupted egg supplies. According to the U.S. Bureau of Labor Statistics and USDA data, the price of eggs in August 2024 increased by 57% year-over-year, while powdered whole egg prices rose by 15%. As a result, food manufacturers are actively seeking egg substitutes to mitigate supply shortages and price volatility. Burcon's canola protein isolate, with over 90% protein purity and exceptional functionality, is a suitable egg replacement in bakery applications. In a side-by-side study, Burcon's canola protein has demonstrated the ability to replace up to 100% of powdered and shelled eggs, delivering cost-in-use savings of 20 - 30%. This great-tasting canola protein not only provides superior functionality and price stability but also offers a vegan-friendly option for consumers. お知らせ • Sep 20
Burcon NutraScience Corporation Announces Board Changes Burcon NutraScience Corporation at its annual general and special meeting of shareholders held on September 18, 2024, announced that, Mr. James Pekar was elected as a director of the Company. Mr. Pekar has over 30 years' of experience in the dairy and food industry. Born and raised in Wisconsin, United States, Mr. Pekar received a full athletic scholarship to attend the University of Iowa to play football. His football career spanned from 1978 to 1987, from playing with the Iowa Hawkeyes to the LA Express and San Antonio Gunslingers, two USFL football teams. In 1994, Mr. Pekar started a dairy based enzyme-modified reaction company, named First Choice Ingredients, which specialized in reaction, fermentation and distillation technologies. Started in the basement of his first home, Mr. Pekar grew First Choice from one employee to over 150 employees and three plants (which included 150,000+ square feet of office and manufacturing space) and operated the business successfully for 27 years. Dr. Lorne Tyrrell retired from the board of directors and did not stand for re-election at the Meeting this year. Breakeven Date Change • Sep 02
Forecast to breakeven in 2026 The analyst covering Burcon NutraScience expects the company to break even for the first time. New forecast suggests losses will reduce by 45% to 2025. The company is expected to make a profit of CA$1.40m in 2026. Average annual earnings growth of 118% is required to achieve expected profit on schedule. お知らせ • Jul 09
Burcon NutraScience Corporation, Annual General Meeting, Sep 18, 2024 Burcon NutraScience Corporation, Annual General Meeting, Sep 18, 2024. お知らせ • Jun 14
Burcon NutraScience Corporation to Report Fiscal Year 2024 Results on Jun 26, 2024 Burcon NutraScience Corporation announced that they will report fiscal year 2024 results on Jun 26, 2024 お知らせ • Mar 13
Burcon NutraScience Corporation announced that it has received CAD 4.36416 million in funding Burcon NutraScience Corporation announced it has completed an over-subscribed non-brokered private placement of 20,298,418 units at an issue price of CAD 0.215 per Unit for gross proceeds of CAD 4,364,159.87 on March 12, 2024. The transaction included participation from company directors, management, long-term shareholders, and new investors in support of it's long-term vision. Each unit consists of one common share in the capital of the Company and one-half of one Common Share purchase warrant of the Company. Each Warrant entitles the holder thereof to purchase one Common Share at a price of CAD 0.27 per Warrant Share for a period of 24 months after the closing date of the Offering. All securities issued in connection with the Offering are subject to a statutory hold period in Canada expiring four months and one day from the closing of the private placement. n connection with the Offering, the Company paid eligible finders an aggregate cash finder fee of CAD 5,160, representing a cash commission of 4% of the gross proceeds of subscribers introduced to the Company by such finders. お知らせ • Feb 01
Burcon NutraScience Corporation to Report Q3, 2024 Results on Feb 14, 2024 Burcon NutraScience Corporation announced that they will report Q3, 2024 results on Feb 14, 2024 お知らせ • Nov 02
Burcon NutraScience Corporation to Report Q2, 2024 Results on Nov 14, 2023 Burcon NutraScience Corporation announced that they will report Q2, 2024 results on Nov 14, 2023 お知らせ • Sep 21
Burcon NutraScience Corporation Announces Board Changes Burcon NutraScience Corporation announced that, Mr. John A. Vassallo was elected as a director of the Company. Mr. Vassallo has over 30 years' experience in asset acquisition, development and management across several industries in multiple states. As Founder and CEO of Mos RE, LLC, Mr. Vassallo focuses on real estate development, land entitlements, redevelopment and strategic reuse of underutilized buildings by utilizing multi-source financing packages, including historic tax credits, tax incremental financing and state development programs. Mr. Vassallo headed multiple capital raises for a variety of developments and acquisitions. Mr. Vassallo also has experience in purchasing distressed debt for profitable returns. As Founder and CEO of Global Restaurant Systems, LLC, Mr. Vassallo established a multi-faceted management and consulting company providing inclusive restaurant development and operating services including accounting, human resources, real estate analysis and acquisition, legal, marketing, IT and administrative support to its clients. Mr. Vassallo currently holds approximately 3.8% of Burcon's issued and outstanding common shares. Mr. J. Douglas Gilpin did not stand for re-election at the Meeting this year. お知らせ • Jul 08
Burcon NutraScience Corporation, Annual General Meeting, Sep 20, 2023 Burcon NutraScience Corporation, Annual General Meeting, Sep 20, 2023. お知らせ • Jun 13
Burcon NutraScience Corporation to Report Fiscal Year 2023 Results on Jun 22, 2023 Burcon NutraScience Corporation announced that they will report fiscal year 2023 results on Jun 22, 2023 お知らせ • May 18
Burcon NutraScience Corporation announced that it has received CAD 3.41342 million in funding On may 16, 2023, the Company has issued a further 3,884,603 Units at a price of CAD 0.265 per Unit for gross proceeds of CAD 1,029,420 for its third and final tranche. Together with the first and second tranche of the Offering, the Company issued a total of 12,880,829 Units for gross proceeds of CAD 3,413,420. In connection with the Offering, the Company paid eligible finders an aggregate cash finder fee of CAD 9,440. お知らせ • May 11
Burcon Announces Sunflower Protein Process Commercially Ready Burcon NutraScience Corporation announce that it has successfully completed end-to-end validation trials of its novel sunflower protein process using commercial-scale equipment at Burcon's Winnipeg Technical Centre. Burcon has validated that its innovative sunflower protein process is robust and ready for commercial scale-up. Burcon's sunflower protein isolates are greater than 90% pure protein, have a neutral flavor profile and are white in color allowing incorporation into many plant-based foods. Initial feedback on Burcon's novel sunflower protein isolate has been overwhelmingly positive. Process validation is a key milestone towards successful commercialization of Burcon's technologies. As part of company's Burcon 2.0 strategy to get closer to customers and end markets, and to have greater control over the manufacture of Burcon's proteins, the Company is evaluating and pursuing multiple routes to market. Discussions with potential partners to bring this technology to market are progressing well, with interested parties wanting to move forward on this project. Concurrent to partnership discussions, Burcon is exploring additional routes to market with the goal of reducing the time required to achieve commercial production and sales. お知らせ • May 10
Burcon NutraScience Corporation announced that it expects to receive CAD 3.376451 million in funding Burcon NutraScience Corporation announced a non-brokered private placement of 12,741,321 units at an issue price of CAD 0.265 per unit for the gross proceeds of CAD 3,376,450 on May 8, 2023. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share at a price of CAD 0.35 per warrant share for a period of 36 months after the closing date of the transaction. All securities issued in connection with the transaction are subject to a statutory hold period in Canada expiring four months and one day from the closing of the transaction. The Transaction is expected to close in two tranches, the first on May 8, 2023 and the second tranche on or before May 11, 2023.
On the same date the company received 5,784,802 units at a price of CAD 0.265 per unit for aggregate gross proceeds of approximately CAD 1,530,000. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share at a price of $0.35 per warrant share for a period of 36 months after the closing date of the offering. All securities issued in connection with the offering are subject to a statutory hold period in Canada expiring four months and one day from the closing of the private placement. The second tranche is expected on or before May 11, 2023. お知らせ • Feb 02
Burcon NutraScience Corporation to Report Q3, 2023 Results on Feb 14, 2023 Burcon NutraScience Corporation announced that they will report Q3, 2023 results on Feb 14, 2023 お知らせ • Nov 24
Burcon NutraScience Corporation Announces Board Changes Burcon NutraScience Corporation announced that at its AGM held on November 23, 2022, the shareholders elected Mr. Aaron T. Ratner as a director of the company, Ms. Rosanna Chau did not stand for re-election at the Meeting in 2022. Mr. Ratner is a Managing Partner and Co-Founder of Vectr Carbon Partners, an early-stage global climate technology venture capital fund manager. He is also the Chief Executive Officer of Clean Earth Acquisitions Corp., as well as an Operating Partner with Nexus PMG. He has over 20 years of domestic and international investment and advisory experience, including eight years in Asia, focusing on project finance, venture capital, climate technology, energy, and agriculture. Mr. Ratner attended the Stanford University Graduate School of Business and completed his undergraduate education at the University of Pennsylvania and Jochi University, Tokyo. お知らせ • Nov 08
Burcon NutraScience Corporation Announces CEO Changes Burcon NutraScience Corporation announced that its Board of Directors has unanimously appointed Kip Underwood, a seasoned veteran executive with over 25 years of experience in the food and specialty protein industry, as Chief Executive Officer, effective November 7, 2022. Peter H. Kappel has relinquished his role as interim CEO and remain as chair of Burcon's board of directors. Mr. Underwood brings deep expertise in sales, marketing, business development and strategy in the specialty protein space. His extensive experience includes executive leadership roles at global companies such as the Solae Company and DuPont Nutrition & Health, where he was responsible for top line sales of $1.4 billion and approximately 250 employees. Known as a champion for growth, Mr. Underwood has led and transformed businesses from multi-year decline into year-over-year growth engines. Kip Underwood: Mr. Underwood began his career with the Solae Company and held progressively more senior positions until he transitioned from the Senior Sales Director for Europe, into the role of Vice President, Specialty Protein Business for DuPont Nutrition and Health. He held the position of NAFTA Regional President with DuPont Nutrition and Health from 2014 - 2017, where he was responsible for top line sales of $1.4 billion and approximately 250 employees. In that role, he achieved above market growth every year in sectors including baking, dairy, beverage, meat and nutritional supplements. Mr. Underwood has extensive experience in leading business turnaround from multi-year sales decline to year-over-year growth. In his latest role at Benson Hill as General Manager and Vice President of Sales, Mr. Underwood led efforts to transform a start-up company to an established food ingredient business including building a $100 million project funnel within the first six months of product launch. He holds an MBA from Saint Louis University and a Bachelor of Science in Chemical Engineering from University of Missouri- Columbia. お知らせ • Oct 25
Burcon NutraScience Corporation to Report Q2, 2023 Results on Nov 07, 2022 Burcon NutraScience Corporation announced that they will report Q2, 2023 results on Nov 07, 2022 お知らせ • Sep 21
Burcon Announces Breakthrough in Sunflower Protein Development Burcon NutraScience Corporation announced that it has developed an plant-based proteins for foods and beverages, announced that it has developed an economical, scalable process to extract high-purity protein ingredients from sunflower seeds for use in foods and beverages. Leveraging its core protein technology platform and expertise, Burcon has developed a proprietary extraction and purification process to convert sunflower meal, a by-product of the production of sunflower oil, into high-quality sunflower protein isolates that feature a neutral taste and off-white color. These unique properties make them ideal for use in a variety of valuable food applications, in particular those featuring delicate flavors. Sunflower proteins currently on the market consist of concentrates in the range of 50-60% protein content, while Burcon's new sunflower protein isolates are greater than 90% pure protein. Like all Burcon proteins, sunflower proteins feature exceptional taste and functional attributes that can address many of the formulation challenges currently facing plant-based protein product developers as they address rising global consumer demands for protein-rich foods and beverages that have clean labels and are natural, tasty and more sustainable. Major Estimate Revision • Aug 22
Consensus revenue estimates fall by 43% The consensus outlook for revenues in 2023 has deteriorated. 2023 revenue forecast decreased from CA$1.05m to CA$600.0k. Forecast losses increased from -CA$0.07 to -CA$0.09 per share. Chemicals industry in Canada expected to see average net income decline 18% next year. Consensus price target down from CA$2.48 to CA$2.28. Share price fell 19% to CA$0.69 over the past week. Reported Earnings • Aug 16
First quarter 2023 earnings: EPS and revenues miss analyst expectations First quarter 2023 results: CA$0.04 loss per share (down from CA$0.029 loss in 1Q 2022). Net loss: CA$4.00m (loss widened 26% from 1Q 2022). Revenue missed analyst estimates by 9.5%. Earnings per share (EPS) also missed analyst estimates by 33%. Over the next year, revenue is forecast to grow 493%, compared to a 9.9% growth forecast for the Chemicals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings. お知らせ • Aug 03
Burcon NutraScience Corporation to Report Q1, 2023 Results on Aug 15, 2022 Burcon NutraScience Corporation announced that they will report Q1, 2023 results on Aug 15, 2022 Major Estimate Revision • Jul 04
Consensus revenue estimates fall by 49% The consensus outlook for revenues in 2023 has deteriorated. 2023 revenue forecast decreased from CA$2.04m to CA$1.05m. Forecast losses increased from -CA$0.01 to -CA$0.07 per share. Chemicals industry in Canada expected to see average net income growth of 4.5% next year. Consensus price target down from CA$3.25 to CA$2.48. Share price was steady at CA$0.53 over the past week. お知らせ • Jul 01
Burcon NutraScience Corporation, Annual General Meeting, Sep 14, 2022 Burcon NutraScience Corporation, Annual General Meeting, Sep 14, 2022. Agenda: Annual General Meeting. Reported Earnings • Jun 28
Full year 2022 earnings: Revenues miss analyst expectations Full year 2022 results: Net loss: CA$10.3m (loss widened CA$9.64m from FY 2021). Revenue missed analyst estimates by 3.7%. Over the next year, revenue is forecast to grow 1,092%, compared to a 29% growth forecast for the industry in Canada. Price Target Changed • Jun 16
Price target decreased to CA$3.25 Down from CA$4.93, the current price target is provided by 1 analyst. New target price is 513% above last closing price of CA$0.53. Stock is down 86% over the past year. The company is forecast to post a net loss per share of CA$0.09 next year compared to a net loss per share of CA$0.006 last year. お知らせ • Jun 14
Burcon NutraScience Corporation to Report Fiscal Year 2022 Results on Jun 27, 2022 Burcon NutraScience Corporation announced that they will report fiscal year 2022 results on Jun 27, 2022 お知らせ • Apr 08
Burcon Receives Nasdaq Letter Regarding Minimum Bid Price Deficiency Burcon NutraScience Corporation announced that on April 1, 2022, the Company received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with Listing Rule 5550 (a)(2), which requires the listed securities of the Company to maintain a minimum bid price of US$1 per share. The Company has not met this requirement for a period of 30 consecutive business days. The Nasdaq notification letter does not result in the immediate delisting of the Company's common shares, and the shares will continue to trade uninterrupted under the symbol "BRCN". The Company has a compliance period of 180 calendar days, or until September 28, 2022, to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the compliance period the Company's closing bid price is at least US$1 for a minimum of 10 consecutive business days, Nasdaq will provide Burcon with a written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance by September 28, 2022, the Company may be eligible for additional time to regain compliance. Burcon's management is reviewing various options available to the Company in order to regain compliance with Nasdaq's listing rules. Buying Opportunity • Apr 07
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 31%. The fair value is estimated to be CA$1.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 89% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 47% per annum. Earnings is also forecast to grow by 61% per annum over the same time period. お知らせ • Mar 03
Burcon NutraScience Corporation Announces Appointment of Peter H. Kappel as Interim CEO Burcon NutraScience Corporation announced that Peter H. Kappel, Chairman of Burcon's board of directors, will assume the role of interim Chief Executive Officer ("CEO"), with immediate effect, until a successor is appointed by the Company's board of directors. Major Estimate Revision • Feb 22
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from CA$230.0k to CA$180.0k. EPS estimate unchanged from -CA$0.09 per share at last update. Chemicals industry in Canada expected to see average net income growth of 35% next year. Consensus price target down from CA$4.93 to CA$4.83. Share price fell 12% to CA$1.21 over the past week. お知らせ • Feb 02
Burcon NutraScience Corporation to Report Q3, 2022 Results on Feb 14, 2022 Burcon NutraScience Corporation announced that they will report Q3, 2022 results on Feb 14, 2022 Price Target Changed • Jan 21
Price target decreased to CA$4.93 Down from CA$6.00, the current price target is an average from 2 analysts. New target price is 263% above last closing price of CA$1.36. Stock is down 70% over the past year. The company is forecast to post a net loss per share of CA$0.09 next year compared to a net loss per share of CA$0.006 last year. Major Estimate Revision • Dec 18
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from CA$470.0k to CA$230.0k. EPS estimate unchanged from -CA$0.09 per share at last update. Chemicals industry in Canada expected to see average net income growth of 36% next year. Consensus price target of CA$5.93 unchanged from last update. Share price fell 2.0% to CA$1.46 over the past week. Reported Earnings • Nov 17
Second quarter 2022 earnings released: CA$0.01 loss per share (vs CA$0.044 profit in 2Q 2021) Second quarter 2022 results: Net loss: CA$1.35m (down 131% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has increased by 94% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Oct 09
Price target decreased to CA$6.00 Down from CA$6.83, the current price target is provided by 1 analyst. New target price is 209% above last closing price of CA$1.94. Stock is down 23% over the past year. Executive Departure • Sep 17
Director Chi Ng has left the company On the 16th of September, Chi Ng's tenure as Director ended after 2.2 years in the role. We don't have any record of a personal shareholding under Chi's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 12.00 years. Executive Departure • Sep 17
Independent Director David Ju has left the company On the 16th of September, David Ju's tenure as Independent Director ended after 3.7 years in the role. We don't have any record of a personal shareholding under David's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 12.00 years. Recent Insider Transactions • Sep 12
Director recently sold CA$87k worth of stock On the 8th of September, Chi Ng sold around 30k shares on-market at roughly CA$2.92 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$171k more than they bought in the last 12 months. Reported Earnings • Aug 21
First quarter 2022 earnings released: CA$0.029 loss per share (vs CA$0.014 loss in 1Q 2021) First quarter 2022 results: Net loss: CA$3.18m (loss widened 127% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has increased by 86% per year, which means it is tracking significantly ahead of earnings growth. Major Estimate Revision • Aug 18
Consensus revenue estimates fall to CA$1.65m The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from CA$3.54m to CA$1.65m. Forecast losses increased from -CA$0.02 to -CA$0.07 per share. Chemicals industry in Canada expected to see average net income growth of 178% next year. Consensus price target of CA$6.67 unchanged from last update. Share price fell 8.1% to CA$2.97 over the past week. Breakeven Date Change • Jul 01
Forecast breakeven pushed back to 2023 The analyst covering Burcon NutraScience previously expected the company to break even in 2022. New forecast suggests the company will make a profit of CA$577.0k in 2023. Average annual earnings growth of 75% is required to achieve expected profit on schedule. Reported Earnings • Jul 01
Full year 2021 earnings released Full year 2021 results: Net loss: CA$617.5k (loss narrowed 87% from FY 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has increased by 91% per year, which means it is tracking significantly ahead of earnings growth. Major Estimate Revision • Feb 10
Analysts lower revenue estimates to CA$100.0k The 2021 consensus revenue estimate decreased from CA$492.5k. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -CA$0.025 to -CA$0.03 for the same period. The Chemicals industry in Canada is expected to see an average net income growth of 59% next year. The consensus price target increased from CA$5.08 to CA$6.25. Share price is up 31% to CA$5.07 over the past week. Is New 90 Day High Low • Feb 05
New 90-day high: CA$4.69 The company is up 92% from its price of CA$2.44 on 06 November 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 30% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$1.59 per share. お知らせ • Jan 30
Burcon NutraScience Corporation to Report Q3, 2021 Results on Feb 16, 2021 Burcon NutraScience Corporation announced that they will report Q3, 2021 results on Feb 16, 2021 Is New 90 Day High Low • Jan 20
New 90-day high: CA$4.59 The company is up 113% from its price of CA$2.15 on 21 October 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 30% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$1.59 per share. Is New 90 Day High Low • Dec 30
New 90-day high: CA$3.22 The company is up 29% from its price of CA$2.50 on 30 September 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 24% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$1.61 per share. Is New 90 Day High Low • Dec 08
New 90-day high: CA$3.11 The company is up 32% from its price of CA$2.35 on 08 September 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 34% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$0.92 per share. Analyst Estimate Surprise Post Earnings • Nov 18
Earnings beat expectations Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 9.1%. Over the next year, revenue is forecast to grow 9,113%, compared to a 33% growth forecast for the Chemicals industry in Canada. Reported Earnings • Nov 18
Second quarter 2021 earnings released: EPS CA$0.04 Second quarter 2021 results: Net income: CA$4.38m (up CA$5.07m from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Sep 25
Independent Director recently sold CA$57k worth of stock On the 18th of September, Peter Kappel sold around 21k shares on-market at roughly CA$2.80 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. お知らせ • Sep 19
Burcon Nutrascience Corporation Elects Rosanna Chau to the Board of Directors Burcon NutraScience Corporation elected Rosanna Chau to the board of directors at the annual meeting of shareholders held on September 17, 2020.